NEW YORK (GenomeWeb News) – Agilent Technologies today announced a deal with BioDiscovery allowing that firm's customers access to Agilent SureFISH probes directly from BioDiscovery's Nexus software.

The deal allows researchers who use different cytogenetic microarray platforms to now quickly identify aberrations with Nexus and to immediately identify and link to available oligonucleotide-based fluorescent in situ hybridization probes for follow-up studies, Agilent said.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genomic analysis of Malaysian tuberculosis strain, database of bat genomes, and more.

An editorial appearing at The Scientist bemoans the high numbers of mitochondrial genome papers and suggests a different path for mitochondrial genome research.

Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.

US lawmakers want to develop a new incarnation of the National Children's Study, ScienceInsider reports.